MetaCap

Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs PMGC (ELAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PMGC is the larger company by market cap ($1.3 million vs $982,950), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDRX+232.56%ELAB-63.69%
+669%+285%-99%
Oct 7, 20261 yearNov 20, 2026
BDRX+307.43%ELAB-62.99%
+681%+291%-98%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDRX versus ELAB key metrics
MetricBDRXELAB
Share price$1.88$1.14
Market cap$982.95K$1.33M
1-day change-3.85%-10.24%
P/E ratio (TTM)0.00—
EPS (TTM)$509.89$-555.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$590.08K
Net income (latest FY)—$-7.75M
Gross margin—31.40%
Net margin—-1313.00%
52-week high$357.60$1,344.00
52-week low$1.85$1.14
Distance from 52-week high-99.48%-99.92%
Analyst consensusnone—
Avg. price target upside+375.20%—
Average volume618.91K279.01K
Shares outstanding524.24K1.17M
Employees1132
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Biodexa Pharmaceuticals American Depositary Shs

BDRX stock →

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About PMGC

ELAB stock →

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.

Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees

BDRX vs ELAB FAQ

Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or PMGC?

PMGC (ELAB) is larger, with a market capitalization of $1.33M compared with $982.95K for Biodexa Pharmaceuticals American Depositary Shs (BDRX).

Are Biodexa Pharmaceuticals American Depositary Shs and PMGC in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons